72716-86-0

Basic information

• Product Name: 4-CYANO-2-METHOXYPYRIDINE
• Synonyms: 4-CYANO-2-METHOXYPYRIDINE;2-METHOXYISONICOTINONITRILE;4-Cyano-2-methoxypyridine 98%;2-cyano-2-Methoxy-1,2-dihydropyridine-4-carboxylic acid;2-Methoxy-4-Pyridinecarbonitrile;4-Pyridinecarbonitrile, 2-methoxy-
• CAS NO: 72716-86-0
• Molecular Formula: C₇H₆N₂O
• Molecular Weight: 134.14
• Product Categories: blocks;Carboxes;Pyridines
• Mol File: 72716-86-0.mol

Chemical Properties

• Melting Point: 88-92
• Boiling Point: 207.1oC at 760 mmHg
• Flash Point: 79.1oC
• Appearance: /
• Density: 1.16g/cm3
• Vapor Pressure: 0.229mmHg at 25°C
• Refractive Index: 1.526
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 0.04±0.10(Predicted)
• CAS DataBase Reference: 4-CYANO-2-METHOXYPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CYANO-2-METHOXYPYRIDINE(72716-86-0)
• EPA Substance Registry System: 4-CYANO-2-METHOXYPYRIDINE(72716-86-0)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 72716-86-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Cyano-2-methoxypyridine is used as a reagent for the synthesis of hydroxypyridone derivatives, which are bioisosters of capsaicin. These derivatives have potential applications in the development of new drugs, particularly those targeting pain relief and other therapeutic areas.
Used in Chemical Synthesis:
In the chemical industry, 4-Cyano-2-methoxypyridine can be utilized as an intermediate in the synthesis of various compounds with diverse applications. Its unique structure allows for further functionalization and modification, making it a valuable building block for the creation of new molecules with specific properties and functions.

InChI:InChI=1/C7H6N2O/c1-10-7-4-6(5-8)2-3-9-7/h2-4H,1H3

Upstream product

• 33252-30-1 2-chloro-4-pyridinenitrile 
• 124-41-4 sodium methylate 
• 20265-39-8 4-amino-2-methoxypyridine 
• 151-50-8 potassium cyanide 
• 865-34-9 lithium methanolate 
• 67-56-1 methanol 

Downstream Products

• 72716-87-1 2-methoxypyridine-4-carboxaldehyde 
• 148900-69-0 (2-methoxy-pyridin-4-yl)-methylamine 
• 880767-50-0 1-(2-methoxypyridin-4-yl)propan-1-one 
• 1029689-75-5 (2-methoxypyridin-4-yl)methanamine hydrochloride 
• 943751-74-4 tert-butyl (2-oxo-1,2-dihydro-pyridin-4-ylmethyl)-carbamate 
• 131052-82-9 4-(aminomethyl)-2(1H)-pyridinone 
• 1354355-10-4 N-((2'-methyl-[2,4'-bipyridin]-5-yl)methyl)-6-phenoxynicotinamide 
• 929972-07-6 2-methoxypyridine-4-carbothioamide 
• 1060806-99-6 1-(2-methoxypyridin-4-yl)cyclopropan-1-amine 
• 123148-66-3 2-methoxy-4-(hydroxymethyl)-pyridine 
• 105596-63-2 2-methoxy-isonicotinic acid 
• 70411-83-5 1-methyl-2-oxo-1,2-dihydropyridine-4-carbonitrile 
• 153901-93-0 5-(2-Methoxy-pyridin-4-ylmethyl)-2-[3-(3-piperidin-1-ylmethyl-phenoxy)-propylamino]-1H-pyrimidin-4-one 

Relevant articles and documents

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections

Conjugating a siderophore to an antibiotic is a promising strategy to overcome the permeability-mediated resistance of Gram-negative pathogens. On the basis of the structure of BAL30072, novel pyridone-conjugated monosulfactams incorporating diverse substituents into the methylene linker between the 1,3-dihydroxypyridin-4(1H)-one and the aminothiazole oxime were designed and synthesized. Structure-activity relationship studies revealed that a variety of substituents were tolerated, with isopropyl (compound 12c) and methylthiomethyl (compound 16a) showing the best efficacy against multidrug-resistant (MDR) Gram-negative pathogens. In addition, compound 12c exhibits a good free fraction rate in an in vitro human plasma protein binding test, along with a low clearance and favorable plasma exposure in vivo. In a murine systemic infection model with MDR Klebsiella pneumoniae, compound 12c shows an ED50 of 10.20 mg/kg. Taken together, the results indicate that compound 12c is a promising drug candidate for the treatment of serious infections caused by MDR Gram-negative pathogens.

Diarylthiazole: An antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system

Diarylthiazole (DAT), a hit from diversity screening, was found to have potent antimycobacterial activity against Mycobacterium tuberculosis (Mtb). In a systematic medicinal chemistry exploration, we demonstrated chemical opportunities to optimize the potency and physicochemical properties. The effort led to more than 10 compounds with submicromolar MICs and desirable physicochemical properties. The potent antimycobacterial activity, in conjunction with low molecular weight, made the series an attractive lead (antibacterial ligand efficiency (ALE) >0.4). The series exhibited excellent bactericidal activity and was active against drug-sensitive and resistant Mtb. Mutational analysis showed that mutations in prrB impart resistance to DAT compounds but not to reference drugs tested. The sensor kinase PrrB belongs to the PrrBA two component system and is potentially the target for DAT. PrrBA is a conserved, essential regulatory mechanism in Mtb and has been shown to have a role in virulence and metabolic adaptation to stress. Hence, DATs provide an opportunity to understand a completely new target system for antimycobacterial drug discovery.

Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4

The series of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-dione and 4-[(pyridylmethyl)aminometh-ylene]isoquinoline-1,3-(2H,4H)-dione derivatives reported here represents a novel class of potential antitumor agents, which potently and selectively inhibit CDK4 over CDK2 and CDK1. In the benzylamino headpiece, a 3-OH substituent is required on the phenyl ring for CDK4 inhibitory activity, which is further enhanced when an iodo, aryl, heteroaryl, t-butyl, or cyclopentyl substituent is introduced at the C-6 position of the isoquinoline-1,3-dione core. To circumvent the metabolic liability associated with the phenolic OH group on the 4-substituted 3-OH phenyl headpiece, we take two approaches: first, introduce a nitrogen o- or p- to the 3-OH group in the phenyl ring; second, replace the phenyl headpiece with N-substituted 2-pyridones. We present here the synthesis, SAR data, metabolic stability data, and a CDK4 mimic model that explains the binding, potency, and selectivity of our CDK4 selective inhibitors.

Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases

Recent studies using known Rho-associated kinase isoform 1 (ROCK1) inhibitors along with cellular and molecular biology data have revealed a pivotal role of this enzyme in many aspects of cardiovascular function. Here we report a series of ROCK1 inhibitors which were originally derived from a dihydropyrimidinone core 1. Our efforts focused on the optimization of dihydropyrimidine 2, which resulted in the identification of a series of dihydropyrimidines with improved pharmacokinetics and P450 properties.

SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE

The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.

NOVEL INHIBITORS OF RHO-KINASES

Novel inhibitors of Rho-kinases are disclosed.

NOVEL PROCESSES FOR THE PRODUCTION OF USEFUL INTERMEDIATES

The present application relates to a new process for the asymmetric production of 3-(pyridin-4-yl)-3-hydroxy-pentanoic acid derivatives, which are useful intermediates in the manufacture of compounds that are known to show antiproliferative activity.

Practical formal total syntheses of the homocamptothecin derivative and anticancer agent diflomotecan via asymmetric acetate aldol additions to pyridine ketone substrates

(Chemical Equation Presented) Two practical, efficient, and scalable asymmetric routes to DE ring fragment 7, a key building block in the synthesis of the homocamptothecin derivative diflomotecan 4, are described. The "acetal route" starts from 2-chloro-4